Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses 06/05/2024 When it comes to cancer drugs, researchers are moving away from a paradigm called the maximum tolerated dose. Instead, they're focusing more on identifying doses that produce fewer side effects but are still effective against a person's cancer. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892